Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: An approach using generalised estimating equations
| Autor: | David Bin-Chia Wu, Vivian W Y Lee, Wai Sau Chung, Edwin Ho Ming Lee, Kenneth K.C. Lee, Danielle Pui Yu Chow, Ming Cheuk Wong |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Cost-Benefit Analysis Estimating equations Drug Administration Schedule Injections Outcome Assessment Health Care Linear regression medicine Humans Adverse effect Psychiatry Biological Psychiatry Aged Retrospective Studies Risperidone business.industry Health Care Costs Middle Aged medicine.disease Confidence interval Hospitalization Psychiatry and Mental health Long acting Psychotic Disorders Schizophrenia Delayed-Action Preparations Cost analysis Hong Kong Regression Analysis Female business Antipsychotic Agents medicine.drug |
| Zdroj: | Psychiatry Research. 210:745-750 |
| ISSN: | 0165-1781 |
| DOI: | 10.1016/j.psychres.2013.07.012 |
| Popis: | Schizophrenia is one of the most expensive psychiatric illnesses. This study compared retrospectively health-care resources consumed 12 months before and 24 months after risperidone long-acting injection (RLAI) treatment in Hong Kong. A mirror-image analysis was conducted using data (N=191) from three public hospitals in Hong Kong from 2003 to 2007. The main outcome measure was hospitalisation cost. Other secondary outcomes such as hospitalisation episodes, outpatient visits and adverse events were also compared. A predictive model was established using linear regression based on generalised estimating equations. Analysis showed that RLAI was associated with a reduction in hospitalisation cost by HK$10,001,390 (24.7%) (HK$40,418,694 vs. HK$30,417,303; P-value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect